Given the task definition and input, reply with output. Given a passage with a context and an answer, construct a question on the basis of the information present in the passage. Construct the question in such a way that (i) it is unambiguous, (ii) it is answerable from the passage, (iii) its answer is unique (iv) it answer uses text phrases from the passage. Avoid creating questions that (i) can't be answered correctly without actually understanding the passage and (ii) uses the same words or phrases given in the passage.

Context: To evaluate the visual and anatomical outcomes of dexamethasone intravitreal implant (DXI; 700g, Ozurdex; Allergan, Irvine, California, USA) as adjunctive therapy for patients with refractory wet age-related macular degeneration (AMD).', 'Retrospective review of the medical records of seven patients (seven eyes) who initially responded well to intravitreal ranibizumab but subsequently developed persistent intra/sub-retinal fluid (IRF/SRF) and underwent a single injection of DXI, between May 2012 and May 2013. Two weeks after DXI, the patients continued with their monthly ranibizumab injections. Best corrected visual acuity (BCVA) logarithm of the minimum angle of resolution (logMAR) and central retinal thickness (CRT) were recorded at baseline, 2weeks, 6weeks, 3months and 6months after DXI injection. Complications were recorded too.', 'All patients had at least 24months of ranibizumab treatment. Mean age was 81.55.8years. At baseline, mean BCVA was 0.530.13 logMAR (20/70 Snellen) and mean CRT was 273.1450.94m. BCVA did not change significantly after DXI over the follow-up period. However, all eyes had lost fewer than 0.3logMAR units. Complete resolution of the persistent IRF/SRF was achieved in five eyes (71.4%) at 6weeks, and remained stable at 3months. Two weeks after DXI injection, the mean CRT diminished compared with baseline (248.2831.8m; p=0.03) and the greatest reduction was observed at 3months after DXI injection (241.536.6m; p=0.04). Progression of lens opacity was detected in one case (50% of phakic eyes). Retreatment with DXI was performed in two eyes.
Answer: DXI appears to be effective in vision stabilisation, decreasing IRF/SRF and improvement of CRT in eyes with refractory wet AMD.
Do dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab?